Purdue's Opioid Rescue Drug Development To Continue Under A New Company
Purdue proposes continuing the development of nalmefene hydrochloride and other products under a new company that would provide the products at no or low cost.
You may also be interested in...
Harm Reduction Therapeutics CEO Michael Hufford says non-profit is “rapidly moving forward” with OTC naloxone NDA.
Consulting firm agrees to turn over tens of thousands of documents detailing its advice to Purdue, J&J, Endo and Mallinckrodt and pay $537m as part of a deal with 47 states.
Filing stays litigation but state attorneys general will be battling company's settlement proposal in US bankruptcy court. Details emerge on Purdue finances, rebate expenditures and litigation costs.